人类免疫缺陷病毒耐药性检测技术及其在非洲资源有限地区的适用性
Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.
作者信息
Nasir Idris Abdullahi, Emeribe Anthony Uchenna, Ojeamiren Iduda, Aderinsayo Adekola Hafeez
机构信息
Department of Medical Microbiology and Parasitology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
Department of Medical Laboratory Services, University of Abuja Teaching Hospital, FCT Abuja, Nigeria.
出版信息
Infect Dis (Auckl). 2017 Dec 19;10:1178633717749597. doi: 10.1177/1178633717749597. eCollection 2017.
Abstract
There has been tremendous breakthrough in the development of technologies and protocols for counselling, testing, and surveillance of resistant human immunodeficiency virus strains for efficient prognosis and clinical management aimed at improving the quality of life of infected persons. However, we have not arrived at a point where services rendered using these technologies can be made affordable and accessible to resource-limited settings. There are several technologies for monitoring antiretroviral resistance, each with unique merits and demerits. In this study, we review the strengths and limitations of prospective and affordable technologies with emphasis on those that could be used in resource-limited settings.
摘要
在用于咨询、检测和监测耐药人类免疫缺陷病毒株以进行有效预后和临床管理的技术及方案的开发方面，已经取得了巨大突破，旨在提高感染者的生活质量。然而，我们尚未达到这样一种程度，即使用这些技术提供的服务能够让资源有限的地区负担得起并可获得。有几种监测抗逆转录病毒耐药性的技术，每种技术都有独特的优缺点。在本研究中，我们回顾了前瞻性且经济实惠的技术的优势和局限性，重点关注那些可在资源有限地区使用的技术。
相似文献
1
Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.人类免疫缺陷病毒耐药性检测技术及其在非洲资源有限地区的适用性
Infect Dis (Auckl). 2017 Dec 19;10:1178633717749597. doi: 10.1177/1178633717749597. eCollection 2017.
2
The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.资源有限环境下用于扩大检测的HIV耐药性诊断的不断演变格局。
AIDS Rev. 2017 Oct-Dec;19(4):219-230.
4
Immune status monitoring of HIV/AIDS patients in resource-limited settings: a review with an emphasis on CD4+ T-lymphocyte determination.资源有限环境下的 HIV/AIDS 患者免疫状态监测：以 CD4+ T 淋巴细胞测定为重点的综述。
Asian Pac J Allergy Immunol. 2012 Mar;30(1):11-25.
5
A Quality Management Approach to Implementing Point-of-Care Technologies for HIV Diagnosis and Monitoring in Sub-Saharan Africa.撒哈拉以南非洲地区实施即时检测技术进行 HIV 诊断和监测的质量管理方法。
J Trop Med. 2012;2012:651927. doi: 10.1155/2012/651927. Epub 2012 Jan 11.
6
Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.南非东开普省一名接受抗逆转录病毒治疗的女性出现的极早期病毒学失败和耐药性突变：病例报告
J Med Case Rep. 2015 May 7;9:106. doi: 10.1186/s13256-015-0557-0.
7
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.负担得起的艾滋病毒耐药性检测，用于监测撒哈拉以南非洲的抗逆转录病毒治疗。
Lancet Infect Dis. 2016 Nov;16(11):e267-e275. doi: 10.1016/S1473-3099(16)30118-9. Epub 2016 Aug 25.
8
The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.评估撒哈拉以南非洲地区艾滋病毒耐药性检测的REVAMP试验：资源有限环境下临床试验设计的案例研究，以优化有效性和成本效益估计。
HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.
9
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.艾滋病毒感染成人急性隐球菌性脑膜炎的治疗，重点关注资源有限的环境。
Cochrane Database Syst Rev. 2008 Oct 8(4):CD005647. doi: 10.1002/14651858.CD005647.pub2.
10
Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings.在资源有限环境中用于艾滋病毒诊断和治疗监测的检测方法开发方面的研究需求与挑战。
Curr Opin HIV AIDS. 2008 Jul;3(4):495-503. doi: 10.1097/COH.0b013e328303e5f9.
引用本文的文献
1
Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV.已归档的 HIV-1 耐药突变：前病毒 HIV-1 DNA 基因型在管理 HIV 病毒学应答者中的作用。
Viruses. 2024 Oct 30;16(11):1697. doi: 10.3390/v16111697.
2
"I feel drug resistance testing allowed us to make an informed decision": qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya.“我觉得耐药性检测让我们能够做出明智的决定”：肯尼亚西部 HIV 阳性儿童和孕妇对 HIV 耐药突变检测作用的定性研究
BMC Health Serv Res. 2023 Aug 24;23(1):908. doi: 10.1186/s12913-023-09804-x.
3
Bayesian variable selection using Knockoffs with applications to genomics.使用仿样变量进行贝叶斯变量选择及其在基因组学中的应用。
Comput Stat. 2022 Sep 18:1-20. doi: 10.1007/s00180-022-01283-8.
4
Antiretroviral (ARV) Drug Resistance and HIV-1 Subtypes among Injecting Drug Users in the Coastal Region of Kenya.肯尼亚沿海地区注射吸毒者中的抗逆转录病毒（ARV）药物耐药性与HIV-1亚型
Adv Virol. 2022 Feb 10;2022:3217749. doi: 10.1155/2022/3217749. eCollection 2022.
5
3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor.3-羟基邻苯二甲酸酐修饰的兔抗PAP IgG作为一种潜在的双功能HIV-1进入抑制剂。
Front Microbiol. 2018 Jun 19;9:1330. doi: 10.3389/fmicb.2018.01330. eCollection 2018.
本文引用的文献
1
The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.资源有限环境下用于扩大检测的HIV耐药性诊断的不断演变格局。
AIDS Rev. 2017 Oct-Dec;19(4):219-230.
2
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.负担得起的艾滋病毒耐药性检测，用于监测撒哈拉以南非洲的抗逆转录病毒治疗。
Lancet Infect Dis. 2016 Nov;16(11):e267-e275. doi: 10.1016/S1473-3099(16)30118-9. Epub 2016 Aug 25.
3
The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study.撒哈拉以南非洲地区成年人到 2030 年需要二线抗逆转录病毒治疗：一项数学建模研究。
Lancet HIV. 2016 Mar;3(3):e132-9. doi: 10.1016/S2352-3018(16)00016-3. Epub 2016 Feb 16.
4
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.在接受基于蛋白酶抑制剂治疗失败的儿科患者中，Gag和蛋白酶对HIV-1表型耐药性的作用。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr.
5
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.HIV-1耐药性突变：即时检验基因分型耐药性检测的潜在应用
PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.
6
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.初治及曾接受拉替拉韦治疗的、感染多种HIV-1进化枝的患者中整合酶抑制剂（INI）的基因型耐药情况。
J Antimicrob Chemother. 2015 Nov;70(11):3080-6. doi: 10.1093/jac/dkv243. Epub 2015 Aug 26.
7
Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.低收入和中等收入国家HIV-1一线抗逆转录病毒治疗的长期病毒学结果：一项系统评价和荟萃分析
Clin Infect Dis. 2015 Nov 1;61(9):1453-61. doi: 10.1093/cid/civ556. Epub 2015 Jul 8.
8
Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.利用多重高通量扩增子测序进行具有成本效益的 HIV-1 耐药性监测：在中低收入国家应用的意义。
J Antimicrob Chemother. 2014 Dec;69(12):3349-55. doi: 10.1093/jac/dku278. Epub 2014 Jul 31.
9
A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.一种用于筛查南非接受一线抗逆转录病毒治疗患者病毒学失败和抗逆转录病毒药物耐药性的定性PCR微池策略。
J Clin Virol. 2014 Aug;60(4):387-91. doi: 10.1016/j.jcv.2014.05.011. Epub 2014 May 29.
10
Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.初治个体中低水平病毒血症时HIV-1耐药性检测的表现及其预测未来病毒学结果和病毒进化的能力。
Clin Infect Dis. 2014 Apr;58(8):1165-73. doi: 10.1093/cid/ciu019. Epub 2014 Jan 14.
Zotero 插件